Shanghai Runda Medical Technology Co., Ltd. Announcement on Adjusting the Company’s 2025 Guarantee Estimate

MaticHoleFiller

2026-03-28 10:52:20

Abstract generation in progress

Stock code: 603108 Stock abbreviation: RunDa Medical Announcement No.: Lin 2026-019

Convertible bond code: 113588 Convertible bond abbreviation: RunDa Convertible Bond

Shanghai RunDa Medical Technology Co., Ltd.

Announcement on Adjusting the Company’s Estimated Guarantees for 2025

The board of directors of the Company and all directors guarantee that the contents of this announcement contain no false records, misleading statements, or material omissions, and assume legal responsibility for the authenticity, accuracy, and completeness of the contents.

Key Information Highlights:

● Guarantee Targets and Basic Information

■

The estimated guarantee amount for the Company’s controlling subsidiary Hangzhou Yidan Biotechnology Co., Ltd. (hereinafter referred to as “Hangzhou Yidan”) is increased from RMB 20,000 million to RMB 23,000 million; a new estimated guarantee of RMB 8,000 million is provided for the Company’s controlling subsidiary Beijing Dongnan Yueda Medical Equipment Co., Ltd. (hereinafter referred to as “Beijing Dongnan”); the estimated guarantee amount for Hangzhou RunDa Medical Management Co., Ltd. (hereinafter referred to as “Hangzhou RunDa”) is reduced from RMB 190,000 million to RMB 179,000 million; the total amount of guarantees the Company expects to provide to subsidiaries remains unchanged. As of the date of disclosure of this announcement, the Company has not provided any guarantees to Beijing Dongnan.

The above guaranteed parties are non-listed-company related parties.

● Cumulative Guarantee Situation

■

For the 2025 fiscal year, the total estimated guarantee amount the Company will provide to its wholly owned and controlling subsidiaries is RMB 422,100 million; the total amount of counter-guarantees that wholly owned subsidiaries provide to the Company for the Company’s issuance of bonds is RMB 90,000 million; together, this represents 117.60% of the Company’s net assets audited for the most recent period.

I. Overview of the Guarantee Adjustment

Pursuant to resolutions approved by the 20th meeting of the fifth session of the board of directors and the 2024 annual general meeting of shareholders, from May 27, 2025 to the date the 2025 annual general meeting of shareholders is held, the Company will provide joint-and-several liability guarantee for guarantee matters related to credit facilities with a total amount not exceeding RMB 422,100 million applied for by the Company’s wholly owned and controlling subsidiaries to (similar) financial institutions. Other shareholders of the controlling subsidiaries will provide corresponding guarantees or provide adequate counter-guarantees to the Company, and the guarantee amount shall correspond to the Company’s actual capital contribution proportion. For details, please refer to the announcement on the Company’s estimated guarantees for 2025 (Announcement No.: Lin 2025-014).

Based on authorization from the Company’s general meeting of shareholders, within the scope of the estimated guarantees for 2025, the Company’s management, according to actual business needs, will adjust the guarantee quotas for the following wholly owned and controlling subsidiaries providing guarantees for the credit facility limits applied for to (similar) financial institutions, as detailed below:

Unit: RMB ten thousand

■

The total estimated guarantee amount for subsidiaries and other matters for 2025 remain unchanged.

II. Basic Information of the Guaranteed Parties

1、Hangzhou Yidan Biotechnology Co., Ltd. (abbreviated as “Hangzhou Yidan”)

■

2、Beijing Dongnan Yueda Medical Equipment Co., Ltd. (abbreviated as “Beijing Dongnan”)

■

III. Main Contents of the Guarantee Agreements

This adjustment relates to the proposed guarantee matters. The relevant guarantee agreements have not yet been signed. Pursuant to authorization from the general meeting of shareholders, the Company will, in accordance with the subsidiaries’ operating capabilities and funding needs and in consideration of market conditions and financing business arrangements, determine the financing method on a best-efforts basis and strictly perform the relevant guarantee matters in accordance with the authorization from the general meeting of shareholders. When guarantee business occurs in practice, the Company will perform information disclosure obligations.

IV. Necessity and Reasonableness of the Guarantees

The loans for which the Company provides guarantees are needed for project construction and daily operations of each subsidiary. This is conducive to accelerating the development of the subsidiaries and is consistent with the Company’s overall development. The Company can monitor the cash flows and financial changes of its wholly owned subsidiaries in real time, and risks are within controllable ranges. Other shareholders of the controlling subsidiaries will provide corresponding guarantees or provide adequate counter-guarantees to the Company, and the guarantee amount the Company actually assumes shall correspond to the capital contribution proportion.

V. Total Number of External Guarantees and Number of Overdue Guarantees

Up to now, the total amount of external guarantees provided by the Company and its controlling subsidiaries is RMB 512,100.00 million (of which the Company provides guarantees to controlling subsidiaries of RMB 422,100.00 million, and subsidiaries provide counter-guarantees to the Company for the Company’s issuance of bonds of RMB 90,000 million). The outstanding balance of guarantees actually incurred is RMB 318,230.47 million, accounting for 73.08% of the net assets audited as of December 31, 2024. There are no overdue guarantees. The total amount of guarantees provided by the Company to controlling subsidiaries is RMB 422,100.00 million, and the outstanding balance of guarantees actually incurred is RMB 318,230.47 million, accounting for 73.08% of the net assets audited as of December 31, 2024. There are no overdue guarantees. The Company does not provide guarantees to controlling shareholders, actual controllers, or their related parties.

This announcement is hereby issued.

Shanghai RunDa Medical Technology Co., Ltd.

Board of Directors

March 26, 2026

For massive information and precise interpretation, everything is in the Sina Finance app

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.